<DOC>
	<DOC>NCT00781820</DOC>
	<brief_summary>The study is focused to prove that the efficacy of a 1% Bifonazole cream is superior to a placebo cream after non-surgical nail ablation with a 40% urea paste.</brief_summary>
	<brief_title>Comparative Efficacy of Bifonazole Cream vs Placebo After Nail Ablation With Urea Paste</brief_title>
	<detailed_description />
	<mesh_term>Onychomycosis</mesh_term>
	<mesh_term>Bifonazole</mesh_term>
	<criteria>Age of at least 18 years; Positive clinical findings of onychomycosis according to the judgement of the investigator (e.g. thickening, discoloration, structural changes, misshaped nails); Positive mycological findings (positive microscopy and positive culture with identification of pathogen) in material taken from affected nail sites before the start of treatment; Nail mycosis with an affected nail area between 20% and 50% in the target nail, Nail mycosis in not more than 3 nails (each nail not more than 50% infected area) Doubtful or negative mycological findings; Proximal subungual onychomycosis (PSO); Topical antimycotic treatment of feet or hands within 4 weeks prior to screening, topical treatment of onychomycosis of feet or hands within 12 weeks prior to screening; Systemic antimycotic treatment within 12 weeks prior to screening; Failure to treat tinea pedis/manus (diagnosed at screening) successfully with topical treatment between screening visit and visit 1 (baseline); Tinea pedis/manus at visit 1 (baseline); Uncontrolled diabetes mellitus Psoriasis Peripheral arterial disease Chronic venous insufficiency; Diabetic neuropathy; History of hypersensitivity to bifonazole, or any other similar pharmacological agents or components of the products; Known sensitivity to plasters.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>Bifonazole</keyword>
	<keyword>Placebo</keyword>
	<keyword>Urea</keyword>
	<keyword>Nail fungus</keyword>
</DOC>